Targeting multi-drug resistant pathogens with synergistic beta-lactams and beta-lactam inhibitor combinations

Background: Infections caused by multidrug-resistant organisms pose a significant global health challenge due to the limited therapeutic options available. Synergistic drug combinations are often employed to enhance treatment efficacy. Because peptidoglycan is unique to prokaryotes, many studies focus on combinations that include beta-lactam antibiotics. To address bacterial strains that produce beta-lactamases, a range of beta-lactamase inhibitors has been developed. The European Committee on Antimicrobial Susceptibility Testing (EUCAST) and the Clinical and Laboratory Standards Institute (CLSI) regularly update clinical guidelines to include standards for new beta-lactam/beta-lactamase inhibitor combinations. Objective: This work provides an overview of beta-lactam and beta-lactamase inhibitor combinations, together with updated clinical guidelines and an analysis of the relevant Protein Data Bank (PDB) entries related to these synergistic combinations. First, the latest EUCAST and CLSI guidelines are reviewed to identify the most recent beta-lactam/beta-lactamase inhibitor combinations used in therapy. Next, PDB entries related to these combinations are examined and compared with new compounds under investigation. EUCAST and CLSI guidelines are valuable for guiding therapeutic strategies, not only for interpreting antibiograms. The newest beta-lactamase inhibitors include avibactam, relebactam, vaborbactam, and enmetazobactam. X-ray crystallography studies have enhanced understanding of inhibitor interactions with major beta-lactamases in Gram-negative pathogens—serine beta-lactamases and metallo-beta-lactamases. Conclusion: Investigating synergistic combinations of beta-lactams and beta-lactamase inhibitors is promising because beta-lactams target peptidoglycan and may enable new therapeutic strategies.

• Publication year

  2026

• Venue

  Journal of Biological Methods

• Publication date

  2026-02-10

• Fields of study

  Not labeled

• Identifiers
  DOI 10.14440/jbm.0299
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Cefepime-enmetazobactam: first approved cefepime-β- lactamase inhibitor combination for multi-drug resistant Enterobacterales

  2025cited by this paper
• Electrostatic interactions influence diazabicyclooctane inhibitor potency against OXA-48-like β-lactamases

  2025cited by this paper
• Antibiotic monotherapy vs dual-drug therapy in perforated appendicitis: single-center retrospective review

  2025cited by this paper
• Clinical outcomes in patients with cancer and Gram-negative bloodstream infection: impact of carbapenem resistance

  2025cited by this paper
• Head-to-head: meropenem/vaborbactam versus ceftazidime/avibactam in ICUs patients with KPC-producing K. pneumoniae infections– results from a retrospective multicentre study

  2025cited by this paper
• A systematic review on natural products with antimicrobial potential against WHO’s priority pathogens

  2025cited by this paper
• The emerging concern of IMP variants being resistant to the only IMP-type metallo-β-lactamase inhibitor, xeruborbactam

  2025influential reference
• Antimicrobial activities and beta-lactamase inhibitory property of actinomycetes from Atlas forest soils in Northeastern Algeria

  2025cited by this paper
• The global resistance problem and the clinical antibacterial pipeline

  2025cited by this paper
• Spectrum of cefepime-taniborbactam coverage against 190 β-lactamases defined in engineered isogenic Escherichia coli strains

  2025cited by this paper
• Genomic approach to evaluate the intrinsic antibacterial activity of novel diazabicyclooctanes (zidebactam and nacubactam) against clinical Escherichia coli isolates from diverse clonal lineages in the United Arab Emirates.

  2025cited by this paper
• The combined dual β-lactams and diazabicyclooctane β-lactamase inhibitor is highly effective against Mycobacterium abscessus species in vitro.

  2025cited by this paper
• PCR Detection of Extended Spectrum β-Lactamase from Some Gram Negative Bacteria of Clinical Source

  2024cited by this paper
• A new class of penicillin-binding protein inhibitors to address drug-resistant Neisseria gonorrhoeae

  2024cited by this paper
• Restoring susceptibility to β-lactam antibiotics in methicillin-resistant Staphylococcus aureus

  2024cited by this paper
• A systematic review of the pharmacokinetics and pharmacodynamics of novel beta-lactams and beta-lactam with beta-lactamase inhibitor combinations for the treatment of pneumonia caused by carbapenem-resistant Gram-negative bacteria.

  2024cited by this paper
• Carbapenemase producing Gram negative bacteria: Review of resistance and detection methods.

  2024cited by this paper
• Combinational antimicrobial activity of biogenic TiO2 NP/ZnO NPs nanoantibiotics and amoxicillin-clavulanic acid against MDR-pathogens.

  2024cited by this paper
• Bioactive Lavandula angustifolia essential oil-loaded nanoemulsion dressing for burn wound healing. In vitro and in vivo studies.

  2023cited by this paper
• Structure-Based Optimization of 1,2,4-Triazole-3-Thione Derivatives: Improving Inhibition of NDM-/VIM-Type Metallo-β-Lactamases and Synergistic Activity on Resistant Bacteria

  2023cited by this paper
• Review of novel β‐lactams and β‐lactam/β‐lactamase inhibitor combinations with implications for pediatric use

  2023cited by this paper
• Sphingomonas paucimobilis bloodstream infection is a predominantly community-onset disease with significant lethality.

  2022cited by this paper
• Intrinsic Antibacterial Activity of Xeruborbactam In Vitro: Assessing Spectrum and Mode of Action

  2022cited by this paper
• Short Communication: Low Prevalence of Clinically Important Antibiotic-Resistant Strains among Non-Pathogenic Genera of the Tribe Klebsielleae

  2022cited by this paper
• Meropenem/Vaborbactam Plus Aztreonam as a Possible Treatment Strategy for Bloodstream Infections Caused by Ceftazidime/Avibactam-Resistant Klebsiella pneumoniae: A Retrospective Case Series and Literature Review

  2022cited by this paper
• In-vitro Antibacterial and Antibiofilm Activity of Cinnamomum verum Leaf Oil against Pseudomonas aeruginosa, Staphylococcus aureus and Klebsiella pneumoniae.

  2021cited by this paper
• Synergistic antibacterial activity of herbal extracts with antibiotics on bacteria responsible for periodontitis.

  2021cited by this paper
• A γ-lactam siderophore antibiotic effective against multidrug-resistant Pseudomonas aeruginosa, Klebsiella pneumoniae, and Acinetobacter spp.

  2021cited by this paper
• Actinomycetes: A Never-Ending Source of Bioactive Compounds—An Overview on Antibiotics Production

  2021cited by this paper
• Imipenem/Cilastatin/Relebactam: A Review in Gram-Negative Bacterial Infections

  2021cited by this paper
• In Vitro Activity of Sulbactam-Durlobactam against Acinetobacter baumannii-calcoaceticus Complex Isolates Collected Globally in 2016 and 2017

  2020cited by this paper
• Kinetic, Thermodynamic, and Crystallographic Studies of 2-Triazolylthioacetamides as Verona Integron-Encoded Metallo-β-Lactamase 2 (VIM-2) Inhibitor

  2020cited by this paper
• A γ-Lactam Siderophore Antibiotic Effective Against Multidrug-Resistant Gram-Negative Bacilli.

  2020cited by this paper
• Clavulanic Acid in the Scope of Helicobacter pylori Treatment: A Literature Review and Beyond.

  2020cited by this paper
• In Vitro Activity of WCK 5222 (Cefepime-Zidebactam) against Worldwide Collected Gram-Negative Bacilli Not Susceptible to Carbapenems

  2020cited by this paper
• A drug-resistant β-lactamase variant changes the conformation of its active-site proton shuttle to alter substrate specificity and inhibitor potency

  2020cited by this paper
• Structural Investigations of the Inhibition of Escherichia coli AmpC β-Lactamase by Diazabicyclooctanes

  2020cited by this paper
• Discovery of ANT3310, a Novel Broad-Spectrum Serine β-Lactamase Inhibitor of the Diazabicyclooctane Class, Which Strongly Potentiates Meropenem Activity against Carbapenem-Resistant Enterobacterales and Acinetobacter baumannii.

  2020cited by this paper
• The Quinazolinone Allosteric Inhibitor of PBP 2a Synergizes with Piperacillin and Tazobactam against Methicillin-Resistant Staphylococcus aureus

  2019cited by this paper
• Interplay between β-lactamases and new β-lactamase inhibitors

  2019cited by this paper
• New Drugs for Multidrug-Resistant Gram-Negative Organisms: Time for Stewardship

  2019cited by this paper
• Antibiotic resistance breakers: current approaches and future directions

  2019cited by this paper
• Essential oil of four medicinal plants and protective properties in plum fruits against the spoilage bacteria and fungi

  2019cited by this paper
• Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-β-lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections

  2019cited by this paper
• Activity of Cefepime-Zidebactam against Multidrug-Resistant (MDR) Gram-Negative Pathogens

  2019cited by this paper
• SAR Studies Leading to the Identification of a Novel Series of Metallo-β-lactamase Inhibitors for the Treatment of Carbapenem-Resistant Enterobacteriaceae Infections That Display Efficacy in an Animal Infection Model

  2018cited by this paper
• ETX2514 is a broad-spectrum β-lactamase inhibitor for the treatment of drug-resistant Gram-negative bacteria including Acinetobacter baumannii

  2017influential reference
• WCK 5222 (cefepime/zidebactam) antimicrobial activity tested against Gram-negative organisms producing clinically relevant &bgr;-lactamases

  2017cited by this paper
• Structural/mechanistic insights into the efficacy of nonclassical β‐lactamase inhibitors against extensively drug resistant Stenotrophomonas maltophilia clinical isolates

  2017cited by this paper
• In vitro antimicrobial synergy of colistin with rifampicin and carbapenems against colistin-resistant Acinetobacter baumannii clinical isolates.

  2016cited by this paper
• Phase 2, Dose-Ranging Study of Relebactam with Imipenem-Cilastatin in Subjects with Complicated Intra-abdominal Infection

  2016cited by this paper
• Penam Sulfones and β-Lactamase Inhibition: SA2-13 and the Importance of the C2 Side Chain Length and Composition

  2014cited by this paper
• Avibactam and Class C β-Lactamases: Mechanism of Inhibition, Conservation of the Binding Pocket, and Implications for Resistance

  2014cited by this paper
• Can Inhibitor-Resistant Substitutions in the Mycobacterium tuberculosis β-Lactamase BlaC Lead to Clavulanate Resistance?: a Biochemical Rationale for the Use of β-Lactam–β-Lactamase Inhibitor Combinations

  2013cited by this paper
• The Importance of the trans‐Enamine Intermediate as a β‐Lactamase Inhibition Strategy Probed in Inhibitor‐Resistant SHV β‐Lactamase Variants

  2012cited by this paper
• Crystal structures of an oligopeptide-binding protein from the biosynthetic pathway of the beta-lactamase inhibitor clavulanic acid.

  2010cited by this paper
• Effect of the inhibitor-resistant M69V substitution on the structures and populations of trans-enamine beta-lactamase intermediates.

  2006cited by this paper
• Structural consequences of the inhibitor-resistant Ser130Gly substitution in TEM beta-lactamase.

  2005cited by this paper
• Inhibitor-resistant class A beta-lactamases: consequences of the Ser130-to-Gly mutation seen in Apo and tazobactam structures of the SHV-1 variant.

  2004cited by this paper
• Recognition and resistance in TEM beta-lactamase.

  2003cited by this paper
• Evolution of an antibiotic resistance enzyme constrained by stability and activity trade-offs.

  2002cited by this paper
• Is Mycobacterium tuberculosis a closer relative to Gram-positive or Gram-negative bacterial pathogens?

  2002cited by this paper
• [Antibiotics and pregnancy].

  2001cited by this paper
• Extended-Spectrum β-Lactamases in the 21st Century: Characterization, Epidemiology, and Detection of This Important Resistance Threat

  2001cited by this paper
• Standard numbering scheme for class B beta-lactamases.

  2001cited by this paper
• Energetic, structural, and antimicrobial analyses of beta-lactam side chain recognition by beta-lactamases.

  2001cited by this paper
• Evolution and spread of SHV extended-spectrum beta-lactamases in gram-negative bacteria.

  1999cited by this paper
• Comparative in-vitro activities of GD-40 and other beta-lactamase inhibitors against TEM-1 and SHV-2 beta-lactamases.

  1998cited by this paper
• A functional classification scheme for beta-lactamases and its correlation with molecular structure

  1995cited by this paper
• A standard numbering scheme for the class A beta-lactamases.

  1991cited by this paper
• A new plasmidic cefotaximase in a clinical isolate of Escherichia coli

  1990cited by this paper
• Sulbactam/Ampicillin, a New Beta-Lactamase Inhibitor/Beta-Lactam Antibiotic Combination

  1988cited by this paper
• The structure of beta-lactamases.

  1980cited by this paper
• Penicillinase Synthesis Controlled By Infectious R Factors In Enterobacteriaceae

  1965cited by this paper

• No citing papers are available for this paper.